Interferon-alpha as a treatment target in systemic lupus erythematosus

Joint Bone Spine

Volumn 79, Issue 2, 2012, Pages 113-116

  Meyer, Olivier ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Interferon alpha; Systemic lupus erythematosus

Indexed keywords

AGS 009; ALPHA INTERFERON; ALPHA INTERFERON DERIVATIVE; CPG 52364; DV 1179; HYDROXYCHLOROQUINE; IMO 3100; INCB 28050; INTERFERON ALPHA KINOID; MEDI 546; MICRORNA INHIBITOR; MICRORNA STIMULATOR; NNC 0152 0000 0001; PLACEBO; PREDNISONE; RONTALIZUMAB; SIFALIMUMAB; TOFACITINIB; UNCLASSIFIED DRUG; VX 509;

ARTHRALGIA; CYTOKINE PRODUCTION; DIARRHEA; EDITORIAL; ENVIRONMENTAL FACTOR; GENE; HEADACHE; HEREDITY; HUMAN; IMMUNOSTIMULATION; NAUSEA; OUTCOME ASSESSMENT; PROMOTER REGION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ENZYME INHIBITORS; HUMANS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROTEIN-TYROSINE KINASES; TOLL-LIKE RECEPTORS;

EID: 84857799686     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.10.013     Document Type: Editorial

References (30)

1. Meyer O. Interferons and autoimmune disorders. Joint Bone Spine 2009, 76:464-473.
2. Crow M.K. Interferon-alpha: a new target for therapy in systemic lupus erythematosus?. Arthritis Rheum 2003, 48:2396-2401.
3. Hooks J.J., Moutsopoulos H.M., Geis S.A., et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979, 301:5-8.
4. Baechler E.C., Batliwalla F.M., Karypis G., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100:2610-2615.
5. Bennett L., Palucka A.K., Arce E., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723.
6. Obermoser G., Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus 2010, 19:1012-1019.
7. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus 2010, 19:419-423.
8. Bauer J.W., Petri M., Batliwalla F.M., et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009, 60:3098-3107.
9. Bauer J.W., Baechler E.C., Petri M., et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Medicine 2006, 3:2274-2284.
10. Fu Q., Chen X., Cui H., et al. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Ther 2008, 10:R112.
11. Moser K.L., Kelly J.A., Lessard C.J., et al. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009, 10:373-379.
12. Delgado-Vega A.M., Alarcon-Riquelme M.E., Kozyrev S.V. Genetic associations in type I interferon related pathways with autoimmunity. Arthritis Res Ther 2010, 12:S2.
13. Harley J.B., James J.A. Everyone comes from somewhere: systemic lupus erythematosus and Epstein-Barr virus induction of host interferon and humoral anti-Epstein-Barr nuclear antigen 1 immunity. Arthritis Rheum 2010, 62:1571-1575.
14. Garcia-Romo G.S., Caielli S., Vega B., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra20.
15. Hakkim A., Furnrohr B.G., Amann K., et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 2010, 107:9813-9818.
16. Richez C., Blanco P., Rifkin I., et al. Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint Bone Spine 2011, 78:124-130.
17. Baccala R., Hoebe K., Kono D.H., et al. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007, 13:543-551.
18. Kontaki E., Boumpas D.T. Innate immunity in systemic lupus erythematosus: sensing endogenous nucleic acids. J Autoimmun 2010, 35:206-211.
19. Ronnblom L., Alm G.V., Eloranta M.L. The type I interferon system in the development of lupus. Semin Immunol 2011, 23:113-121.
20. Duffau P., Seneschal J., Nicco C., et al. Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med 2010, 2:47ra63.
21. Zhou H., Huang X., Cui H., et al. miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells. Blood 2010, 116:5885-5894.
22. Barrat F.J., Meeker T., Chan J.H., et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007, 37:3582-3586.
23. Riggs J.M., Cibotti R., Liang M., et al. Mechanism of action of sifalimumab, a human neutralizing IFN alpha specific monoclonal antibody. Ann Rheum Dis 2011, 70:123.
24. Petri M., Wallace D.J., Spindler A., et al. Sifalimumab, a fully human anti-interferon-alpha monoclonal antibody in subjects with systemic lupus erythematosus (SLE): results of a phase 1B randomized, placebo-controlled, dose-escalation intravenous study. Ann Rheum Dis 2011, 70:125.
25. Morehouse C., Liu Z., Higgs B.W., et al. A type I IFN gene signature is used to measure PD and correlates with both IFN protein and two instruments used to assess disease activity at baseline in systemic lupus erythematosus in a phase 1B clinical trial. Ann Rheum Dis 2011, 70:78.
26. Yao Y., Richman L., Higgs B.W., et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009, 60:1785-1796.
27. Merrill J.T., Chindalore V., Box J., et al. Results of a randomized, placebo-controlled, phase 2A study of sifalimumab, an anti-inerferon-alpha monoclonal antibody, administered subcutaneously in subjects with systemic lupus erythematosus. Ann Rheum Dis 2011, 70:314.
28. Houssiau F., Raskhov R., Hachulla E., et al. Therapeutic against IFN alpha in lupus patients: a phase I-II clinical study of IFN kinoid. Ann Rheum Dis 2011, 70:738.
29. Zagury D., Le Buanec H., Mathian A., et al. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci USA 2009, 106:5294-5299.
30. Dupuis S., Jouanguy E., Al-Hajjar S., et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet 2003, 33:388-391.